Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

HCI researchers find cell mechanism that may trigger pancreatic cancer

Researchers at Huntsman Cancer Institute at the University of Utah have found that defects in how cells are squeezed out of overcrowded tissue to die, a process called extrusion, may be a mechanism by which pancreatic cancer begins. From these findings, they may have identified an effective way to reverse the defective extrusion's effects without destroying normal tissues nearby.

28 Jan 2015

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer.

20 Jan 2015

MET amplified in NSCLC irrespective of type, genetic background

A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds.

20 Jan 2015

New guidance recommends use of primary HPV test for cervical cancer screening

About 80 million U.S. women ages 25 to 65 should be screened periodically by their health care providers for cervical cancer. At present, the standard way to do that is a Pap smear alone, or co-testing using both a Pap smear and a human papillomavirus (HPV) test.

8 Jan 2015

Next generation sequencing in malignant pleural mesothelioma tumors reveals complex mutational setting

Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.

23 Dec 2014

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests.

18 Dec 2014

Sugar-based molecular microcapsule eliminates toxicity of anticancer agent

Johns Hopkins researchers have developed a sugar-based molecular microcapsule that eliminates the toxicity of an anticancer agent developed a decade ago at Johns Hopkins, called 3-bromopyruvate, or 3BrPA, in studies of mice with implants of human pancreatic cancer tissue. The encapsulated drug packed a potent anticancer punch, stopping the progression of tumors in the mice, but without the usual toxic effects.

18 Dec 2014

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows.

12 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

CT screening highly sensitive, specific for lung cancer detection

Low-dose computed tomography screening for lung cancer has high specificity and high sensitivity, with just a small number of interval cancers, finds an interim analysis of the NELSON trial.

19 Nov 2014

Mayo Clinic study finds that chromosomal rearrangements can help trace lineage of lung cancer

A diagnostic test based on chromosomal rearrangements can trace the lineage of lung cancer to determine whether two separate lung cancers in the same patient are independent tumors or a tumor that has spread to another region of the lung, a Mayo Clinic study has found. For patients with multiple tumors, that distinction could mean the difference between early stage cancer that may be cured by surgery and incurable late-stage disease.

12 Nov 2014

Researchers explain interaction between HNRNPA2B1 protein and pancreatic cancer development

Researchers from the University of Barcelona have described an interaction between the protein HNRNPA2B1 and pancreatic cancer development which remained unknown. The study, published in the journal Gastroenterology, has proved in human cancer cell lines that this protein is essential to the correct activity of the oncogenic protein KRAS, related to cancer start and development.

11 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Study compares five-year DFS and OS rates for patients with AIS and MIA

Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS), according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

PORT can improve survival for non-small cell lung cancer patients

Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology.

31 Oct 2014

Simple blood test may help spot pancreatic cancer

Indiana University cancer researchers have found that a simple blood test might help diagnose pancreatic cancer, one of the most deadly forms of the disease.

28 Oct 2014

MIT researchers develop new way to model effects of cancer-causing genetic mutations

Sequencing the genomes of tumor cells has revealed thousands of genetic mutations linked with cancer. However, sifting through this deluge of information to figure out which of these mutations actually drive cancer growth has proven to be a tedious, time-consuming process.

24 Oct 2014

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals.

10 Oct 2014

Study addresses the challenge of genomic heterogeneity

Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published today in Science.

10 Oct 2014

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients.

30 Sep 2014